Simple and Fast Assay for Apolipoprotein E Phenotyping and Glycotyping: Discovering Isoform-Specific Glycosylation in Plasma and Cerebrospinal Fluid

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2020 Jun 23

PMID 32568201

Citations 16

Authors

Yueming Hu

Cristiana Meuret

Scholastica Go

Hussein N Yassine

Dobrin Nedelkov

Affiliations

Soon will be listed here.

Abstract

Background: The mechanisms of how APOEɛ4 allele (APOE4) increases the risk of Alzheimer's disease (AD) pathology have not been fully elucidated. In cerebrospinal fluid (CSF), apoE is heavily glycosylated.

Objective: To determine the impact of APOE genotype on the relative abundance of apoE protein isoforms and their specific glycosylation patterns in CSF and plasma via a newly developed mass spectrometric immunoassay (MSIA) assay.

Methods: Total glycosylation and isoform-specific glycosylation were analyzed in plasma and CSF from a group of non-demented older individuals (n = 22), consisting of homozygous ɛ3 and ɛ4 or heterozygous ɛ3/ɛ4, ɛ2/ɛ3, or ɛ2/ɛ4 carriers. The glycan structures were further confirmed after treatment with sialidase.

Results: In heterozygous individuals, the apoE3/E2, E4/E2, and E4/E3 isoform ratios were all significantly lower in plasma compared to CSF. For all individuals, a single O-linked glycan was observed in plasma, while two glycans (of the same type) per apoE were observed in CSF. The ratio of glycosylated to total apoE was greater in CSF compared to plasma for all apoE isoforms. In plasma and CSF, a trend of decreasing glycosylation was observed from apoE2 > apoE3 > apoE4. The difference in the percentage of secondary glycosylation in CSF was significantly greater in apoE4 compared to the other isoforms.

Conclusion: The new MSIA apoE assay robustly distinguishes among apoE isoforms and glycoforms in plasma and CSF. ApoE4 is the predominant isoform and least glycosylated in CSF. Assessing apoE isoform-specific glycosylation by MSIA may help clarify brain apoE metabolism and AD risk.

Citing Articles

Readdressing the Localization of Apolipoprotein E (APOE) in Mitochondria-Associated Endoplasmic Reticulum (ER) Membranes (MAMs): An Investigation of the Hepatic Protein-Protein Interactions of APOE with the Mitochondrial Proteins Lon Protease....

Rueter J, Rimbach G, Bilke S, Tholey A, Huebbe P Int J Mol Sci. 2024; 25(19).

PMID: 39408926 PMC: 11476584. DOI: 10.3390/ijms251910597.

Human apolipoprotein E glycosylation and sialylation: from structure to function.

Moon H, Luo Y, Chugh D, Zhao L Front Mol Neurosci. 2024; 17:1399965.

PMID: 39169951 PMC: 11335735. DOI: 10.3389/fnmol.2024.1399965.

Isoform- and cell-state-specific APOE homeostasis and function.

Lindner K, Gavin A Neural Regen Res. 2024; 19(11):2456-2466.

PMID: 38526282 PMC: 11090418. DOI: 10.4103/NRR.NRR-D-23-01470.

APOE4 genotype and aging impair injury-induced microglial behavior in brain slices, including toward Aβ, through P2RY12.

Sepulveda J, Kim J, Binder J, Vicini S, Rebeck G Mol Neurodegener. 2024; 19(1):24.

PMID: 38468308 PMC: 10929239. DOI: 10.1186/s13024-024-00714-y.

New insight into protein glycosylation in the development of Alzheimer's disease.

Zhao J, Lang M Cell Death Discov. 2023; 9(1):314.

PMID: 37626031 PMC: 10457297. DOI: 10.1038/s41420-023-01617-5.

References

Liu F, Iqbal K, Grundke-Iqbal I, Hart G, Gong C . O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101(29):10804-9. PMC: 490015. DOI: 10.1073/pnas.0400348101. View

Bales K, Liu F, Wu S, Lin S, Koger D, Delong C . Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci. 2009; 29(21):6771-9. PMC: 6665579. DOI: 10.1523/JNEUROSCI.0887-09.2009. View

Zhao N, Liu C, Qiao W, Bu G . Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. Biol Psychiatry. 2017; 83(4):347-357. PMC: 5599322. DOI: 10.1016/j.biopsych.2017.03.003. View

Flowers S, Grant O, Woods R, Rebeck G . O-glycosylation on cerebrospinal fluid and plasma apolipoprotein E differs in the lipid-binding domain. Glycobiology. 2019; 30(2):74-85. PMC: 7335482. DOI: 10.1093/glycob/cwz084. View

Liu M, Kuhel D, Shen L, Hui D, Woods S . Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am J Physiol Regul Integr Comp Physiol. 2012; 303(9):R903-8. PMC: 3517701. DOI: 10.1152/ajpregu.00219.2012. View

Zhu C, Wong M, Li Q, Sawrey-Kubicek L, Beals E, Rhodes C . Site-Specific Glycoprofiles of HDL-Associated ApoE are Correlated with HDL Functional Capacity and Unaffected by Short-Term Diet. J Proteome Res. 2019; 18(11):3977-3984. PMC: 7480961. DOI: 10.1021/acs.jproteome.9b00450. View

Blanchard V, Ramin-Mangata S, Billon-Crossouard S, Aguesse A, Durand M, Chemello K . Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study. J Lipid Res. 2018; 59(5):892-900. PMC: 5928431. DOI: 10.1194/jlr.P083576. View

Kawasaki K, Ogiwara N, Sugano M, Okumura N, Yamauchi K . Sialic acid moiety of apolipoprotein E and its impact on the formation of lipoprotein particles in human cerebrospinal fluid. Clin Chim Acta. 2009; 402(1-2):61-6. DOI: 10.1016/j.cca.2008.12.018. View

Strittmatter W, Saunders A, Schmechel D, Pericak-Vance M, Enghild J, Salvesen G . Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90(5):1977-81. PMC: 46003. DOI: 10.1073/pnas.90.5.1977. View

10.

Marmillot P, Rao M, Liu Q, Lakshman M . Desialylation of human apolipoprotein E decreases its binding to human high-density lipoprotein and its ability to deliver esterified cholesterol to the liver. Metabolism. 1999; 48(9):1184-92. DOI: 10.1016/s0026-0495(99)90136-1. View

11.

Lauer S, Corsini A, Walker D, Taylor J, Rall Jr S . Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. J Biol Chem. 1989; 264(15):9094-101. View

12.

Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

13.

Chua C, Lim M, Wong B . Altered apolipoprotein E glycosylation is associated with Abeta(42) accumulation in an animal model of Niemann-Pick Type C disease. J Neurochem. 2010; 112(6):1619-26. DOI: 10.1111/j.1471-4159.2010.06586.x. View

14.

Dhavale D, Henry J . Evaluation of sialic acid-analogs for the attenuation of amyloid-beta toxicity. Biochim Biophys Acta. 2012; 1820(10):1475-80. DOI: 10.1016/j.bbagen.2012.04.018. View

15.

Sugano M, Yamauchi K, Kawasaki K, Tozuka M, Fujita K, Okumura N . Sialic acid moiety of apolipoprotein E3 at Thr(194) affects its interaction with beta-amyloid(1-42) peptides. Clin Chim Acta. 2007; 388(1-2):123-9. DOI: 10.1016/j.cca.2007.10.024. View

16.

Zannis V, vanderSpek J, Silverman D . Intracellular modifications of human apolipoprotein E. J Biol Chem. 1986; 261(29):13415-21. View

17.

Fukumoto H, Ingelsson M, Garevik N, Wahlund L, Nukina N, Yaguchi Y . APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol. 2003; 183(1):249-53. DOI: 10.1016/s0014-4886(03)00088-8. View

18.

Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

19.

Pitas R, Boyles J, Lee S, Foss D, Mahley R . Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987; 917(1):148-61. DOI: 10.1016/0005-2760(87)90295-5. View

20.

Patel D, Henry J, Good T . Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers. Biochim Biophys Acta. 2006; 1760(12):1802-9. DOI: 10.1016/j.bbagen.2006.08.008. View